Atualização em reações de hipersensibilidade aos anti-inflamatórios não esteroidais – Parte 1: definições, farmacologia, epidemiologia, fisiopatologia e fatores genéticos
Update on hypersensitivity reactions to nonsteroidal anti-inflammatory drugs – Part 1: definitions, pharmacology, epidemiology, pathophysiology, and genetics
Marcelo Vivolo Aun; Rosana Câmara Agondi; Diogo Costa Lacerda; Ullissis Pádua Menezes; Maria Inês Perelló; Adriana Teixeira Rodrigues; Ana Carolina D'Onofrio-Silva; Tânia Maria Gonçalves Gomes; Luiz Alexandre Ribeiro da-Rocha; Denise Neiva Santos de Aquino; Fernanda Casares Marcelino; Gladys Queiroz; Maria Fernanda Malaman; Inês Cristina Camelo-Nunes; Mara Morelo Rocha Felix
Resumo
Os anti-inflamatórios não esteroidais (AINE) estão entre os medicamentos mais utilizados no mundo e são os fármacos mais frequentemente associados à ocorrência de reações de hipersensibilidade na América Latina. As reações têm grande variabilidade de apresentações clínicas e, consequentemente, com abordagem terapêutica difícil. Nesta revisão, abordamos aspectos farmacológicos dos AINE, bem como as definições, epidemiologia e fisiopatologia das reações de hipersensibilidade aos AINE. Por fim, discutimos aspectos genéticos associados à intolerância e alergia a esses fármacos.
Palavras-chave
Abstract
Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most commonly used medications worldwide and the drugs most frequently associated with the occurrence of hypersensitivity reactions in Latin America. The clinical presentation of the reactions varies widely, which makes them difficult to treat. In this review, we address pharmacological aspects of NSAIDs, as well as the definitions, epidemiology, and pathophysiology of hypersensitivity reactions to NSAIDs. Finally, we discuss genetic factors associated with intolerance and allergy to these drugs.
Keywords
Referências
1. Jin J. Nonsteroidal Anti-inflammatory Drugs. JAMA. 2015 Sep 8;314(10):1084.
2. Kowalski ML, Asero R, Bavbek S, Blanca M, Blanca-Lopez N, Bochenek G, et al. Classification and practical approach to the diagnosis and management of hypersensitivity to nonsteroidal anti-inflammatory drugs. Allergy. 2013 Oct;68(10):1219-32.
3. Bacchi S, Palumbo P, Sponta A, Coppolino MF. Clinical pharmacology of non-steroidal anti-inflammatory drugs: a review. Antiinflamm Antiallergy Agents Med Chem. 2012;11(1):52-64.
4. Smith W. Adverse drug reactions - allergy? side-effect? intolerance? Aust Fam Physician. 2013;42(1-2):12-6.
5. Johansson SG, Bieber T, Dahl R, Friedmann PS, Lanier B, Lockey R, et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol. 2004;113(5):832-6.
6. Demoly P, Adkinson NF, Brockow K, Castells M, Chiriac AM, Greenberger PA, et al. International Consensus on drug allergy. Allergy. 2014;69(4):420-37.
7. Whitehouse MW, Haslam JM. Ability of some antirheumatic drugs to uncouple oxidative phosphorylation. Nature. 1962;196:1323-4.
8. Spector WG, Willoughby DA. Anti-inflammatory effects of salicylate in the rat. In: Dixon A StJ, Martin BK, Smith MJH, Wood PHN, eds. Salicylates: An International Symposium. Boston: Little, Brown, 1963:141-7.
9. Phillips WJ, Currier BL. Analgesic pharmacology: II. Specific analgesics. J Am Acad Orthop Surg. 2004 Jul-Aug;12(4):221-33.
10. Kumar V, Abbas AK, Aster JC. Robbins & Cotran: Patologia – Bases patológicas das doenças. 9ªed. Rio de Janeiro: Elsevier; 2016. p. 71-114.
11. Bjarnason I, Scarpignato C, Holmgren E, Olszewski M, Rainsford KD, Lanas A. Mechanisms of Damage to the Gastrointestinal Tract From Nonsteroidal Anti-Inflammatory Drugs. Gastroenterology. 2018;154(3):500‑14.
12. Chaiamnuay S, Allison JJ, Curtis JR. Risks versus benefits of cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs. Am J Health Syst Pharm. 2006 Oct 01;63(19):1837-51.
13. Arfè A, Scotti L, Varas-Lorenzo C, Nicotra F, Zambon A, Kollhorst B, Schink T, Garbe E, et al.; Safety of Non-steroidal Anti-inflammatory Drugs (SOS) Project Consortium. Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ. 2016 Sep 28;354:i4857.
14. Bindu S, Mazumder S, Bandyopadhyay U. Non-steroidal antiinflammatory drugs (NSAIDs) and organ damage: A current perspective. Biochem Pharmacol. 2020;180:114147.
15. Murray MD, Brater DC Renal toxicity of the nonsteroidal antiinflamatórios. Annu. Rev. Pharmacol. Toxicol. 1993;33:435‑65.
16. Davies NM, Good RL, Roupe KA, Yáñez JA. Cyclooxygenase-3: axiom, dogma, anomaly, enigma or splice error? Not as easy as 1, 2, 3. J Pharm Pharm Sci. 2004 Jul 9;7(2):217-26.
17. Gupta A, Bah M. NSAIDs in the Treatment of Postoperative Pain. Curr Pain Headache Rep. 2016 Nov;20(11):62.
18. Blanca-Lopez N, Soriano V, Garcia-Martin E, Canto G, Blanca M. NSAID-induced reactions: classification, prevalence, impact, and management strategies. J Asthma Allergy. 2019 Aug 8;12:217‑33.
19. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA. 1999 Jun 22;96(13):7563-8.
20. Blanca-López N, Cornejo-García JA, Plaza-Serón MC, Doña I, Torres-Jaén MJ, Canto G, et al. Hypersensitivity to Nonsteroidal Antiinflammatory Drugs in Children and Adolescents: Cross-Intolerance Reactions. J Investig Allergol Clin Immunol. 2015;25(4):259-69.
21. Blanca M, Whitaker P. Advances in hypersensitivity drug reactions. Curr Opin Allergy Clin Immunol. 2018 Aug;18(4):281-3.
22. Baldo BA, Pham NH. Non-steroidal Anti-inflammatory Drugs. In: Drug allergy: clinical aspects, diagnosis, mechanisms, structureactivity relationships. 2ª ed. Springer; 2021. p. 439-71.
23. Kowalski ML, Makowska JS, Blanca M, Bavbek S, Bochenek G, Bousquet J, et al. Hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs) - classification, diagnosis and management: review of the EAACI/ENDA(#) and GA2LEN/HANNA*. Allergy. 2011 Jul;66(7):818-29.
24. Cavkaytar O, du Toit G, Caimmi D. Characteristics of NSAID-induced hypersensitivity reactions in childhood. Pediatr Allergy Immunol. 2019 Feb;30(1):25-35.
25. Kidon M, Blanca-Lopez N, Gomes E, Terreehorst I, Tanno L, Ponvert C, et al. EAACI/ENDA Position Paper: Diagnosis and management of hypersensitivity reactions to non-steroidal anti-inflammatory drugs (NSAIDs) in children and adolescents. Pediatr Allergy Immunol. 2018 Aug;29(5):469-80.
26. Doña I, Pérez-Sánchez N, Eguiluz-Gracia I, Muñoz-Cano R, Bartra J, Torres MJ, et al. Progress in understanding hypersensitivity reactions to nonsteroidal anti-inflammatory drugs. Allergy. 2020 Mar;75(3):561-75.
27. Giavina-Bianchi P, Jares E, Aun MV, Thong B. Drug hypersensitivity reactions in the Americas: Similarities and differences. Ann Allergy Asthma Immunol. 2019 May;122(5):447-8.
28. Aun MV, Blanca M, Garro LS, Ribeiro MR, Kalil J, Motta AA, et al. Nonsteroidal anti-inflammatory drugs are major causes of drug-induced anaphylaxis. J Allergy Clin Immunol Pract. 2014 JulAug;2(4):414-20.
29. Jares EJ, Cardona Villa R, Sánchez-Borges M, de Falco A, Ensina LF, Bernstein JA, et al. Drug-induced anaphylaxis, elicitors, risk factors, and management in Latin America. J Allergy Clin Immunol Pract. 2020 Apr;8(4):1403-5.
30. Agondi RC, Dias GMFS, Assis JP, Pacheco R, Kalil J, Giavina-Bianchi P. Hypersensitivity to dipyrone in aspirin-exacerbated respiratory disease patients is associated with urticaria. Respir Med. 2020 Aug-Sep;170:106041.
31. Ariza A, García-Martín E, Salas M, Montañez MI, Mayorga C, Blanca-Lopez N, et al. Pyrazolones metabolites are relevant for identifying selective anaphylaxis to metamizole. Sci Rep. 2016 Mar 31;6:23845.
32. Pichler WJ. Immune pathomechanism and classification of drug hypersensitivity. Allergy. 2019;74(8):1457-71.
33. Yeung WYW, Park HS. Update on the Management of Nonsteroidal Anti-Inflammatory Drug Hypersensitivity. Yonsei Med J. 2020;61(1):4‑14.
34. Lee TH, Christie PE. Leukotrienes and aspirin induced asthma. Thorax. 1993;48(12):1189-90.
35. Walters KM, Woessner KM. An Overview of Nonsteroidal Antiinflammatory Drug Reactions. Immunol Allergy Clin North Am. 2016 Nov;36(4):625-41.
36. Plaza-Serón MDC, García-Martín E, Agúndez JA, Ayuso P. Hypersensitivity reactions to nonsteroidal anti-inflammatory drugs: an update on pharmacogenetics studies. Pharmacogenomics. 2018 Aug 1;19(13):1069-86.
37. Jurado-Escobar R, Doña I, Perkins JR, Laguna JJ, Muñoz-Cano R, García-Sánchez A, et al. Polymorphisms in eicosanoid-related biosynthesis enzymes associated with acute urticaria/angioedema induced by nonsteroidal anti-inflammatory drug hypersensitivity. Br J Dermatol. 2021 Oct;185(4):815-24.
38. García-Martín E, García-Menaya JM, Esguevillas G, CornejoGarcía JA, Doña I, Jurado-Escobar R, et al. Deep sequencing of prostaglandin-endoperoxide synthase (PTGE) genes reveals genetic susceptibility for cross-reactive hypersensitivity to NSAID. Br J Pharmacol. 2021 Mar;178(5):1218-33.
39. Blanca M, Oussalah A, Cornejo-García JA, Blanca-López N, GuéantRodriguez RM, Doña I, et al. GNAI2 variants predict nonsteroidal anti-inflammatory drug hypersensitivity in a genome-wide study. Allergy. 2020 May;75(5):1250-3.
40. Kim JH, Park BL, Cheong HS, Bae JS, Park JS, Jang AS, et al. Genome-wide and follow-up studies identify CEP68 gene variants associated with risk of aspirin-intolerant asthma. PLoS One. 2010 Nov 3;5(11):e13818.
41. Cornejo-García JA, Flores C, Plaza-Serón MC, Acosta-Herrera M, Blanca-López N, Doña I, et al. Variants of CEP68 gene are associated with acute urticaria/angioedema induced by multiple non-steroidal anti-inflammatory drugs. PLoS One. 2014 Mar 11;9(3):e90966.
42. Perkins JR, Acosta-Herrera M, Plaza-Serón MC, Jurado-Escobar R, Doña I, García-Martín E,et al. Polymorphisms in CEP68 gene associated with risk of immediate selective reactions to nonsteroidal anti-inflammatory drugs. Pharmacogenomics J. 2019 Apr;19(2):191-9.
43. Park BL, Kim TH, Kim JH, Bae JS, Pasaje CF, Cheong HS, et al. Genome-wide association study of aspirin-exacerbated respiratory disease in a Korean population. Hum Genet. 2013 Mar;132(3):313‑21.
44. Choi JH, Lee KW, Oh HB, Lee KJ, Suh YJ, Park CS, et al. HLA association in aspirin-intolerant asthma: DPB1*0301 as a strong marker in a Korean population. J Allergy Clin Immunol. 2004 Mar;113(3):562-4.
Submetido em:
17/03/2022
Aceito em:
25/06/2022
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email